Funded by Centers for Disease Control and Prevention Overdose Data to Action (OD2A) grant, this website was created in part by the University of Hawaiʻi at Mānoa and the Hawaiʻi State Department of Health, and made possible by ongoing collaboration with the following partners:
- Department of the Medical Examiner, City & County of Honolulu
- Department of Public Safety
- Hawaiʻi Police Department
- Interagency Council on Intermediate Sanctions, including:
- Judiciary, State of Hawaii
- Department of Public Safety, State of Hawaii
- Department of the Attorney General, State of Hawaii
- Office of the Public Defender, State of Hawaii
- Hawaii Paroling Authority, State of Hawaii
- Department of the Prosecuting Attorney, City & County of Honolulu
- Honolulu Police Department, City & County of Honolulu
- Kauaʻi Police Department
- Laulima Data Alliance
- Maui Police Department
We gratefully acknowledge all staff who continue to build, maintain, and support this website.
About the Overdose Data to Action project
Overdose Data to Action (OD2A) is a CDC cooperative agreement aimed at (1) expanding public health surveillance to allow for higher quality and more timely and comprehensive data collection for drug-related misuse and overdose morbidity and mortality, and (2) using these data to drive prevention strategies. The project has multiple surveillance and prevention focal points, including strengthening state and local capacity for public health programs; connecting health systems, state and local partners and agencies, and community members to improve prescribing practices and share data; increasing access and usability of the Prescription Drug Monitoring Program; improving treatment access and engagement; and building awareness among our community.
Common terms used in this dashboard:
- Substance use disorder (SUD): “occur[s] when the use of alcohol and/or drugs causes
clinically significant impairment, including health problems, disability, and failure to
meet major responsibilities at work, school, or home” 1
- Co-occurring disorders: disorders that a person experiences at the same time. In this
dashboard, we present data on people with a substance use disorder who may also
experience co-occurring mental illness, or vice versa (people with mental illness who
may also experience co-occurring substance use disorder).
- Polysubstance use: use or consumption of more than one drug at the same time or
within a short period of time of each other.
- Behavioral Health: emotional, psychological, and social aspects of health or well-being,
including mental health and substance use.
- Crisis: “an acute emotional upset; it is manifested in an inability to cope emotionally,
cognitively, or behaviorally and to solve problems as usual.” 2 Signs of a crisis may
include feeling like something is wrong without being able to explain the reason for it,
feeling hopeless, panicked, trapped, empty, or in a lot of pain, and nothing seems to help.
- Substance Abuse and Mental Health Services Administration (2022) Mental health and
substance use disorders SAMHSA. Available at: https://www.samhsa.gov/find-
hool%2C%20or%20home (Accessed: January 30, 2023).
- Centers for Disease Control and Prevention (2020) Crisis: A definition Available at:
ute%20emotional,usual%20(Hoff%2C%202009 (Accessed: January 30, 2023).
For Drug Overdose Surveillance & Epidemiology (DOSE)
Discharge Data Case Definitions:
Each category below includes unintentional, intentional self-harm (analyzed separately), and
undetermined intent poisonings for the initial encounter only–does not include assault, adverse
effect, or underdosing.
- All Drug: poisoning by drugs, medicaments and biological substances—does not include
assault, adverse effect, underdosing; initial encounter only—does not include subsequent
encounter(s) or sequela;
- All Opioids: poisoning by opium, heroin, other opioids, methadone, synthetic narcotics,
fentanyl or fentanyl analogs, tramadol, synthetic narcotics, unspecified narcotics, and
- Heroin: poisoning by heroin
- Stimulants: poisoning by cocaine, unspecified psychostimulants, caffeine,
amphetamines, methylphenidate, ecstasy, and other psychostimulants
Important Data Considerations:
- Missing Data: discharge data submitted by state/jurisdiction health departments can be
delayed or temporarily stalled. Once data sharing resumes, emergency department visit or
hospitalizations not shared during the initial data exchange, may not be backfilled or shared.
- Data overlap: drug overdose visit counts are not mutually exclusive and represent the
nesting of drug categories (i.e., suspected all drug category includes the number of suspected
opioid-, heroin-, and stimulant-involved overdose visits; suspected heroin counts are included
in the suspected opioid category; and cases that involve multiple substances can include both
opioids and stimulants).
- Reporting delays: as states/jurisdictions continue to onboard new data-sharing facilities to
support syndromic surveillance activities, some facilities experience occasional interruptions
in data availability. Data may also evolve over time (e.g., introducing new diagnosis codes).
As a result, reported cases and rates can change over time.
- Suspected overdoses/poisonings: these data are not necessarily verified by toxicological
testing and are considered “suspected” overdoses, not confirmed cases.
- Undercounts: data likely represent an undercount when accounting for inaccuracies in
- “Technical Guidance for the Drug Overdose Surveillance and Epidemiology (DOSE)
System: Version 2.4.” CDC: Centers for Disease Control & Prevention, pg. 41, October
- “Drug Overdose Surveillance & Epidemiology (DOSE) Dashboard: Nonfatal Overdose
Data.” CDC: Centers for Disease Control and Prevention, Important Data